Ann: Lumos Receives Second US$5 million Hologic IP Payment, page-43

Definitely not new news. The only question was the exact timing.

The market is sitting back waiting for more sales/revenue data so they can do some sums on just how FebriDx affects LDX.

The market wants more in terms of guidance from the company, however the ASX does not allow for that information to be announced, so the share price is in a quandary until we get a few quarterlies behind us.

From what Doug was saying in the investor briefing we aren't likely to get a feel for its penetration into the US market until we have the sales figures for the September quarter. The bulk of the winter supplies for these tests are generally bought or ordered by that time.